Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
Ian G McKeith, Bradley F Boeve, Dennis W Dickson, Glenda Halliday, John-Paul Taylor, Daniel Weintraub, Dag Aarsland, James Galvin, Johannes Attems, Clive G Ballard, Ashley Bayston, Thomas G Beach, Frédéric Blanc, Nicolaas Bohnen, Laura Bonanni, Jose Bras, Patrik Brundin, David Burn, Alice Chen-Plotkin, John E Duda, Omar El-Agnaf, Howard Feldman, Tanis J Ferman, Dominic Ffytche, Hiroshige Fujishiro, Douglas Galasko, Jennifer G Goldman, Stephen N Gomperts, Neill R Graff-Radford, Lawrence S Honig, Alex Iranzo, Kejal Kantarci, Daniel Kaufer, Walter Kukull, Virginia M Y Lee, James B Leverenz, Simon Lewis, Carol Lippa, Angela Lunde, Mario Masellis, Eliezer Masliah, Pamela McLean, Brit Mollenhauer, Thomas J Montine, Emilio Moreno, Etsuro Mori, Melissa Murray, John T O'Brien, Sotoshi Orimo, Ronald B Postuma, Shankar Ramaswamy, Owen A Ross, David P Salmon, Andrew Singleton, Angela Taylor, Alan Thomas, Pietro Tiraboschi, Jon B Toledo, John Q Trojanowski, Debby Tsuang, Zuzana Walker, Masahito Yamada, Kenji Kosaka, Ian G McKeith, Bradley F Boeve, Dennis W Dickson, Glenda Halliday, John-Paul Taylor, Daniel Weintraub, Dag Aarsland, James Galvin, Johannes Attems, Clive G Ballard, Ashley Bayston, Thomas G Beach, Frédéric Blanc, Nicolaas Bohnen, Laura Bonanni, Jose Bras, Patrik Brundin, David Burn, Alice Chen-Plotkin, John E Duda, Omar El-Agnaf, Howard Feldman, Tanis J Ferman, Dominic Ffytche, Hiroshige Fujishiro, Douglas Galasko, Jennifer G Goldman, Stephen N Gomperts, Neill R Graff-Radford, Lawrence S Honig, Alex Iranzo, Kejal Kantarci, Daniel Kaufer, Walter Kukull, Virginia M Y Lee, James B Leverenz, Simon Lewis, Carol Lippa, Angela Lunde, Mario Masellis, Eliezer Masliah, Pamela McLean, Brit Mollenhauer, Thomas J Montine, Emilio Moreno, Etsuro Mori, Melissa Murray, John T O'Brien, Sotoshi Orimo, Ronald B Postuma, Shankar Ramaswamy, Owen A Ross, David P Salmon, Andrew Singleton, Angela Taylor, Alan Thomas, Pietro Tiraboschi, Jon B Toledo, John Q Trojanowski, Debby Tsuang, Zuzana Walker, Masahito Yamada, Kenji Kosaka
Abstract
The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- McKeith IG, Galasko D, Kosaka K, et al. . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113–1124.
- McKeith IG, Dickson DW, Lowe J, et al. . Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology 2005;65:1863–1872.
- Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med 2014;44:673–683.
- Tiraboschi P, Attems J, Thomas A, et al. . Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load. Neurology 2015;84:496–499.
- Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007;69:356–359.
- Toledo JB, Cairns NJ, Da X, et al. . Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 2013;1:65.
- Hansen L, Salmon D, Galasko D, et al. . The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology 1990;40:1–8.
- Hamilton JM, Landy KM, Salmon DP, Hansen LA, Masliah E, Galasko D. Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. Am J Geriatr Psychiatry 2012;20:773–781.
- Ferman TJ, Smith GE, Boeve BF, et al. . Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006;20:623–636.
- Yokoi K, Nishio Y, Uchiyama M, Shimomura T, Iizuka O, Mori E. Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia 2014;56:245–254.
- Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015;386:1683–1697.
- Galvin JE. Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimers Dement 2015;1:316–324.
- Bradshaw JSM, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004;75:382–387.
- Ferman TJ, Smith GE, Boeve BF, et al. . DLB fluctuations: specific features that reliably differentiate from AD and normal aging. Neurology 2004;62:181–187.
- Walker MP, Ayre GA, Cummings JL, et al. . The clinician assessment of fluctuation and the one day fluctuation assessment scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252–256.
- Lee DR, McKeith I, Mosimann U, et al. . The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 2014;22:926–935.
- Mosimann UP, Collerton D, Dudley R, et al. . A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry 2008;23:712–718.
- Postuma RB, Berg D, Stern M, et al. . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1599.
- Ferman TJ, Boeve BF, Smith GE, et al. . Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011;77:875–882.
- Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009;72:1296–1300.
- Iranzo A, Fernandez-Arcos A, Tolosa E, et al. . Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One 2014;9:e89741.
- Boeve BF, Silber MH, Ferman TJ, et al. . Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013;14:754–762.
- Boeve BF, Molano JR, Ferman TJ, et al. . Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445–453.
- Postuma RB, Arnulf I, Hogl B, et al. . A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 2012;27:913–916.
- Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80:667–670.
- McKeith I, O'Brien J, Walker Z, et al. . Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–313.
- Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012;135:2798–2808.
- Yoshita M, Arai H, Arai H, et al. . Diagnostic accuracy of I-123-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study. PLoS One 2015;10:e0120540.
- Tiraboschi P, Corso A, Guerra UP, et al. . (123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: a comparative study. Ann Neurol 2016;80:368–378.
- Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. . Medial temporal lobe atrophy on MRI differentiates Alzheimers disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132:195–203.
- Harper L, Fumagalli GG, Barkhof F, et al. . MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain 2016;139:1211–1225.
- Nedelska Z, Ferman TJ, Boeve BF, et al. . Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015;36:452–461.
- Higuchi M, Tashiro M, Arai H, et al. . Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000;162:247–256.
- Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–365.
- Lobotesis K, Fenwick JD, Phipps A, et al. . Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001;56:643–649.
- O'Brien JT, Firbank MJ, Davison C, et al. . F-18-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med 2014;55:1959–1965.
- Lim SM, Katsifis A, Villemagne VL, et al. . The F-18-FDG PET cingulate island sign and comparison to I-123-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009;50:1638–1645.
- Graff-Radford J, Murray ME, Lowe VJ, et al. . Dementia with Lewy bodies basis of cingulate island sign. Neurology 2014;83:801–809.
- Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimers disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008;131:690–705.
- Petrou M, Dwamena BA, Foerster BR, et al. . Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015;30:928–935.
- Kantarci K, Lowe VJ, Boeve BF, et al. . Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33:2091–2105.
- Guerreiro R, Escott-Price V, Darwent L, et al. . Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiol Aging 2016:38;214.e7–214.e10.
- Peuralinna T, Myllykangas L, Oinas M, et al. . Genome-wide association study of neocortical Lewy-related pathology. Ann Clin Transl Neurol 2015;2:920–931.
- Guella I, Evans DM, Szu-Tu C, et al. . Alpha-synuclein genetic variability: a biomarker for dementia in Parkinson disease. Ann Neurol 2016;79:991–999.
- Boot BP. Comprehensive treatment of dementia with Lewy bodies. Alzheimers Res Ther 2015;7:45.
- Uc EY, Doerschug KC, Magnotta V, et al. . Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 2014;83:413–425.
- Wang HF, Yu JT, Tang SW, et al. . Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015;86:135–143.
- Stinton C, McKeith I, Taylor JP, et al. . Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 2015;172:731–742.
- McKeith I, Del Ser T, Spano P, et al. . Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
- McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673–678.
- Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356–1363.
- Cummings J, Isaacson S, Mills R, et al. . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383:533–540.
- Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23:2248–2250.
- Aurora RN, Zak RS, Maganti RK, et al. . Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010;6:85–95.
- Montine TJ, Phelps CH, Beach TG, et al. . National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012;123:1–11.
- Beach TG, Adler CH, Lue L, et al. . Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009;117:613–634.
- Fujishiro H, Tsuboi Y, Lin W-L, Uchikado H, Dickson DW. Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer's disease with amygdala Lewy bodies. Acta Neuropathol 2008;116:17–24.
- Uchikado H, Lin W-L, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 2006;65:685–697.
- Alafuzoff I, Parkkinen L, Al-Sarraj S, et al. . Assessment of alpha-synuclein pathology: a study of the BrainNet Europe consortium. J Neuropathol Exp Neurol 2008;67:125–143.
- Dickson DW, Braak H, Duda JE, et al. . Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150–1157.
Source: PubMed